Research Analysts Issue Forecasts for CVRx Q2 Earnings

CVRx, Inc. (NASDAQ:CVRX - Free Report) - Analysts at William Blair issued their Q2 2025 EPS estimates for CVRx in a research report issued to clients and investors on Monday, July 7th. William Blair analyst B. Vazquez anticipates that the company will post earnings of ($0.52) per share for the quarter. William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for CVRx's current full-year earnings is ($1.91) per share. William Blair also issued estimates for CVRx's Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($2.00) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.39) EPS and FY2026 earnings at ($1.96) EPS.

CVRx (NASDAQ:CVRX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.03. The firm had revenue of $12.35 million during the quarter, compared to analysts' expectations of $14.68 million. CVRx had a negative net margin of 97.49% and a negative return on equity of 79.04%.

Several other research firms also recently issued reports on CVRX. Lake Street Capital lowered their price objective on CVRx from $19.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, April 8th. Canaccord Genuity Group lowered their price objective on CVRx from $23.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, April 8th. Piper Sandler lowered their price objective on CVRx from $20.00 to $12.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Finally, JPMorgan Chase & Co. reaffirmed an "underweight" rating and issued a $7.00 price objective (down previously from $15.00) on shares of CVRx in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, CVRx presently has an average rating of "Moderate Buy" and an average price target of $14.50.

CVRx Stock Performance

CVRx stock opened at $6.96 on Thursday. The business has a 50 day moving average of $6.40 and a 200-day moving average of $10.37. CVRx has a 1 year low of $4.30 and a 1 year high of $18.55. The company has a debt-to-equity ratio of 0.71, a current ratio of 14.82 and a quick ratio of 13.45. The company has a market capitalization of $181.45 million, a P/E ratio of -3.19 and a beta of 1.23.

Insider Activity at CVRx

In related news, Director Kirk G. Nielsen acquired 10,966 shares of CVRx stock in a transaction dated Thursday, May 15th. The stock was bought at an average price of $5.45 per share, with a total value of $59,764.70. Following the transaction, the director directly owned 1,910,134 shares in the company, valued at $10,410,230.30. This represents a 0.58% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have purchased 78,666 shares of company stock worth $411,031. Company insiders own 13.90% of the company's stock.

Institutional Trading of CVRx

Several large investors have recently modified their holdings of the stock. Parkman Healthcare Partners LLC lifted its holdings in shares of CVRx by 33.5% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,229,522 shares of the company's stock worth $15,037,000 after purchasing an additional 308,348 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of CVRx by 10,520.1% in the 4th quarter. JPMorgan Chase & Co. now owns 628,286 shares of the company's stock worth $7,960,000 after purchasing an additional 622,370 shares in the last quarter. Emerald Advisers LLC lifted its holdings in shares of CVRx by 47.3% in the 4th quarter. Emerald Advisers LLC now owns 593,898 shares of the company's stock worth $7,525,000 after purchasing an additional 190,844 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in shares of CVRx in the 1st quarter worth $4,852,000. Finally, Silvercrest Asset Management Group LLC bought a new position in shares of CVRx in the 4th quarter worth $4,713,000. Institutional investors and hedge funds own 75.27% of the company's stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.